Influence of TCF7L2 gene polymorphisms on the effectiveness of various variants of antihyperglycaemic therapy in patients with type 2 diabetes

Q3 Medicine

Voprosy Detskoi Dietologii Pub Date : 2021-01-01 DOI:10.20953/2224-5448-2021-2-11-20

О.V. Kondratyeva, K. Sharafetdinov, O. A. Plotnikova

{"title":"Influence of TCF7L2 gene polymorphisms on the effectiveness of various variants of antihyperglycaemic therapy in patients with type 2 diabetes","authors":"О.V. Kondratyeva, K. Sharafetdinov, O. A. Plotnikova","doi":"10.20953/2224-5448-2021-2-11-20","DOIUrl":null,"url":null,"abstract":"Single nucleotide polymorphisms of the TCF7L2 gene demonstrate the strongest association with the risk of developing type 2 diabetes, linking its effects to changes in insulin secretion. The mechanism of action of hypoglycaemic drugs used in treatment of type 2 diabetes is, to a certain extent, related to their influence on the function of β-cells, which implies that variants of the TCF7L2 gene will affect the therapeutic effect of certain anti-hyperglycaemic drugs, including the variability in the effects of incretin-based therapy, and sulphonylurea derivatives. Along with the direct influence of the TCF7L2 gene on the function of β-cells, there is evidence of the effects of TCF7L2 gene polymorphism on the susceptibility to external risk factors associated with the development of type 2 diabetes, including the alimentary factors. Pharmacogenetic studies in diabetology have at present the greatest potential in terms of selection of the optimal comprehensive anti-hyperglycaemic therapy based on preliminary genetic testing, which might improve the outcomes of treatment and the prognosis for the course of type 2 diabetes, reducing the number of life-threatening complications. Key words: GPP-1 agonists, TCF7L2 gene, metformin, nutrition, type 2 diabetes, sulphonylureas","PeriodicalId":53444,"journal":{"name":"Voprosy Detskoi Dietologii","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy Detskoi Dietologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/2224-5448-2021-2-11-20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Single nucleotide polymorphisms of the TCF7L2 gene demonstrate the strongest association with the risk of developing type 2 diabetes, linking its effects to changes in insulin secretion. The mechanism of action of hypoglycaemic drugs used in treatment of type 2 diabetes is, to a certain extent, related to their influence on the function of β-cells, which implies that variants of the TCF7L2 gene will affect the therapeutic effect of certain anti-hyperglycaemic drugs, including the variability in the effects of incretin-based therapy, and sulphonylurea derivatives. Along with the direct influence of the TCF7L2 gene on the function of β-cells, there is evidence of the effects of TCF7L2 gene polymorphism on the susceptibility to external risk factors associated with the development of type 2 diabetes, including the alimentary factors. Pharmacogenetic studies in diabetology have at present the greatest potential in terms of selection of the optimal comprehensive anti-hyperglycaemic therapy based on preliminary genetic testing, which might improve the outcomes of treatment and the prognosis for the course of type 2 diabetes, reducing the number of life-threatening complications. Key words: GPP-1 agonists, TCF7L2 gene, metformin, nutrition, type 2 diabetes, sulphonylureas

查看原文本刊更多论文

TCF7L2基因多态性对2型糖尿病患者各种抗高血糖治疗效果的影响

TCF7L2基因的单核苷酸多态性与患2型糖尿病的风险密切相关，将其影响与胰岛素分泌的变化联系起来。用于治疗2型糖尿病的降糖药物的作用机制在一定程度上与其对β细胞功能的影响有关，这意味着TCF7L2基因的变异会影响某些降糖药物的治疗效果，包括以肠促胰岛素为基础的治疗效果的变异性，以及磺脲类衍生物。随着TCF7L2基因对β-细胞功能的直接影响，有证据表明TCF7L2基因多态性对2型糖尿病发生相关的外部危险因素易感性的影响，包括饮食因素。目前，糖尿病学的药物遗传学研究在基于初步基因检测选择最佳综合抗高血糖疗法方面具有最大的潜力，这可能改善2型糖尿病的治疗结果和预后，减少危及生命的并发症的数量。关键词:GPP-1激动剂，TCF7L2基因，二甲双胍，营养，2型糖尿病，磺脲类药物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Voprosy Detskoi Dietologii Medicine-Pediatrics, Perinatology and Child Health

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： The scientific journal Voprosy Detskoi Dietologii is included in the Scopus database. Publisher country is RU. The main subject areas of published articles are Food Science, Pediatrics, Perinatology, and Child Health, Nutrition and Dietetics, Клиническая медицина.